BASF introduces Hepaxa in the U.S. for non-alcoholic fatty liver disease patients
February 22, 2018BASF Corporation is introducing Hepaxa, a product that can help tens of millions of patients manage Non-Alcoholic Fatty Liver Disease (NAFLD), one of the most common forms of chronic liver disease.
Providing highly concentrated and pure eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), Hepaxa is the first product in the U.S. specifically designed to address a buildup of fat in the liver, known as steatosis, in NAFLD patients, BASF said in its press release.
Hepaxa is manufactured using a patented purification technology removing persistent organic pollutants and other unwanted lipids such as cholesterol, which are naturally found in all fish oil-based products. Research has shown that one specific pollutant, PCB 153, is particularly harmful to NAFLD patients. The liver function of NAFLD patients is compromised and it is important to avoid additional exposure to unwanted components of traditional fish oil.
Christoph Garbotz, Head of Commercial Management Advanced Health Solutions, BASF, said: BASF’s launch of Hepaxa is the result of our research and development efforts targeting liver health, where we are capitalizing on our unique scientific competencies. With NAFLD rapidly becoming a major public health concern worldwide, we are proud to now offer this first-to-market, dedicated solution for NAFLD patients in the U.S.”
